V Meeting of the European Forum on Antiphospholipid Antibodies

Autoimmunity Reviews

Volumn 5, Issue 7, 2006, Pages 499-507

  Cervera, Ricard ^a   Font, Josep ^a   Tincani, Angela ^b   Boffa, Marie Claire ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b Ospedale Civile di Brescia   (Italy)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Anticardiolipin antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; Lupus anticoagulant

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; IMMUNOPATHOGENESIS; LABORATORY TEST; REVIEW; STANDARDIZATION;

ANIMALS; ANTIPHOSPHOLIPID SYNDROME; HUMANS; PHOSPHOLIPIDS;

EID: 33747182601     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.01.001     Document Type: Review

References (26)

1. Miyakis S., Atsumi T., Lockshin M.D., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definte antiphospholipid syndrome (APS). J. Thrombos. Haemostas. 4 (2006) 295-306
2. Reber G., Tincani A., Sanmarco M., de Moerloose P., and Boffa M.C. Standardization group of the European Forum on Antiphospholipid Antibodies. Proposals for the measurement of anti-beta2-glycoprotein I antibodies. Standardization group of the European forum on antiphospholipid antibodies. J Thromb Haemost 2 (2004) 1860-1862
3. Tincani A., Allegri F., Balestrieri G., Reber G., Sanmarco M., Meroni P., et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on Antiphospholipid Antibodies. Thromb Res 114 (2004) 553-558
4. Reber G., Schousboe I., Tincani A., Sanmarco M., Kveder T., de Moerloose P., et al. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies standardization group. Thromb Haemost 88 (2002) 66-73
5. Ambrožič A., Božič B., Kveder T., Majhenc J., Arrigler V., Svetina S., et al. Budding, vesiculation, permeabilization of phospholipids membranes-evidence for a feasible. Physiologic role of β2-glycoprotein I and pathogenic action of anti-β2-glycoprotein I antibodies. Biochim Biophys Acta 1740 (2005) 38-44
6. Tincani A., Spatola L., Prati E., Allegri F., Ferremi P., Cattaneo R., et al. The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. J Immunol 157 (1996) 5732-5738
7. Sanmarco M., Bardin N., Blank M., Pascal V., Christine Alessi M., Dignat-George F., et al. Heterogeneity of anti-beta2-glycoprotein I antibodies. A factor of variability in test results. Thromb Haemost 93 (2005) 80-87
8. Gris J.C., Quere I., Sanmarco, Boutiere B., Mercier E., Amiral J., et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists study-NOHA. Thromb Haemost 84 (2000) 228-236
9. Sugi T., Matsubayashi H., Inomo A., Dan L., and Makino T. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. J Obstet Gynaecol Res 30 (2004) 326-332
10. Sanmarco M., Alessi M.C., Harle J.R., Sapin C., Aillaud M.F., Gentile S., et al. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost 85 (2001) 800-805
11. Sanmarco M., Gayet S., Alessi M.C., Audrain M., Boneu B., de Maistre E., et al. Report on the European collaborative study on APE antibodies. Thromb Res 114 (2004) 636 [abstract]
12. De Lemos J.A., Zirlik A., Schonbeck U., Varo N., Murphy S.A., Khera A., et al. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 25 (2005) 2192-2196
13. Karassa F.B., Bijl M., Davies K.A., Kallenberg C.G., Khamashta M.A., Manger K., et al. Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum 48 (2003) 1930-1938
14. Manger K., Repp R., Jansen M., Geisselbrecht M., Wassmuth R., Westerdaal N.A., et al. Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms. Ann Rheum Dis 61 (2002) 786-792
15. Baumann I., Kolowos W., Voll R.E., Manger B., Gaipl U., Neuhuber W.L., et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 46 (2002) 191-201
16. Gaipl U.S., Franz S., Voll R.E., Sheriff A., Kalden J.R., and Herrmann M. Defects in the disposal of dying cells lead to autoimmunity. Curr Rheumatol Rep 6 (2004) 401-407
17. Gaipl U.S., Beyer T.D., Baumann I., Voll R.E., Stach C.M., Heyder P., et al. Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal-implications for antiphospholipid syndrome and systemic lupus erythematosus. Immunobiology 207 (2003) 73-81
18. Gaipl U.S., Brunner J., Beyer T.D., Voll R.E., Kalden J.R., and Herrmann M. Disposal of dying cells: a balancing act between infection and autoimmunity. Arthritis Rheum 48 (2003) 6-11
19. Carmona F., Font J., Azulay M., Creus M., Fàbregues F., Cervera R., et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol 46 (2001) 274-279
20. Boffa M.C., Aurousseau M.H., Lachassinne E., Dauphin H., Fain O., Le Toumelin P., et al. European register of babies born to mothers with antiphospholipid syndrome. Lupus 13 (2004) 713-717
21. Frances C., Niang S., Laffitte E., Pelletier F.L., Costedoat N., and Piette J.C. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum 52 (2005) 1785-1793
22. Toubi E., Krause I., Fraser A., Lev S., Stojanovich L., Rovensky J., et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 23 (2005) 499-504
23. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46 (2002) 1019-1027
24. Shoenfeld Y., Blank M., Cervera R., Font J., Raschi E., and Meroni P.L. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 65 (2006) 2-6
25. Asherson R.A., Cervera R., de Groot P.G., Erkan D., Boffa M.C., Piette J.C., et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12 (2003) 530-534
26. Cervera R., Font J., Gómez-Puerta J.A., Espinosa G., Cucho M., Bucciarelli S., et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 64 (2005) 1205-1209